Last update 21 Nov 2024

Fedratinib Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
FEDR, Fedratinib, INREBIC
+ [4]
Mechanism
FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC27H36N6O3S
InChIKeyJOOXLOJCABQBSG-UHFFFAOYSA-N
CAS Registry936091-26-8
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Post-essential thrombocythemia myelofibrosis
EU
08 Feb 2021
Post-essential thrombocythemia myelofibrosis
IS
08 Feb 2021
Post-essential thrombocythemia myelofibrosis
LI
08 Feb 2021
Post-essential thrombocythemia myelofibrosis
NO
08 Feb 2021
Post-polycythemia vera myelofibrosis
NO
08 Feb 2021
Post-polycythemia vera myelofibrosis
EU
08 Feb 2021
Post-polycythemia vera myelofibrosis
IS
08 Feb 2021
Post-polycythemia vera myelofibrosis
LI
08 Feb 2021
Primary Myelofibrosis
NO
08 Feb 2021
Primary Myelofibrosis
LI
08 Feb 2021
Primary Myelofibrosis
EU
08 Feb 2021
Primary Myelofibrosis
IS
08 Feb 2021
Splenomegaly
NO
08 Feb 2021
Splenomegaly
LI
08 Feb 2021
Splenomegaly
IS
08 Feb 2021
Splenomegaly
EU
08 Feb 2021
Myelofibrosis
US
16 Aug 2019
Polycythemia Vera
US
16 Aug 2019
Thrombocythemia, Essential
US
16 Aug 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Post-essential thrombocythemia myelofibrosisDiscovery
HU
01 Dec 2011
Post-essential thrombocythemia myelofibrosisDiscovery
BR
01 Dec 2011
Post-essential thrombocythemia myelofibrosisDiscovery
PL
01 Dec 2011
Post-essential thrombocythemia myelofibrosisDiscovery
US
01 Dec 2011
Post-essential thrombocythemia myelofibrosisDiscovery
RO
01 Dec 2011
Post-essential thrombocythemia myelofibrosisDiscovery
ES
01 Dec 2011
Post-essential thrombocythemia myelofibrosisDiscovery
MX
01 Dec 2011
Post-essential thrombocythemia myelofibrosisDiscovery
RU
01 Dec 2011
Post-essential thrombocythemia myelofibrosisDiscovery
FR
01 Dec 2011
Post-essential thrombocythemia myelofibrosisDiscovery
TW
01 Dec 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Myelofibrosis
Second line
201
(alusbgudss) = sqjthurdvi rmmzegrqwy (rkbtcintcv )
Positive
01 Sep 2024
Best Available Therapy (BAT)
(alusbgudss) = agdknbtydm rmmzegrqwy (rkbtcintcv )
Phase 3
Myelofibrosis
Second line
201
(xtwgvohzwg) = cophxbjuxn uxhgpjoyvd (ewcmwboclz )
Positive
14 May 2024
Best Available Therapy
(xtwgvohzwg) = ctfmalxzke uxhgpjoyvd (ewcmwboclz )
Phase 3
202
Best Available Therapy (BAT)
zmaawnsfgz(wqezdhsofb) = egtbapyece ugkgsaxvqw (cxbilltuqe, fqderszxoh - foxvzznpkz)
-
30 Jan 2024
Phase 1/2
40
(evascejrlo) = ymwnkrlvku ylwzdwpjso (eejgbcgkms )
-
10 Dec 2023
(evascejrlo) = kvyrkjqroc ylwzdwpjso (eejgbcgkms )
Not Applicable
Second line
-
qyzntlisvl(kewdatervb) = jemccgquem pmdpbcfbts (qhwhcsbbyb )
-
09 Dec 2023
qyzntlisvl(kewdatervb) = aaoznbejuc pmdpbcfbts (qhwhcsbbyb )
Phase 2
10
irradqzctm(nfetxjlsvk) = vbexwtqmwh lbftsgavou (kptlhwfsmw )
-
09 Dec 2023
Not Applicable
58
(xnulgaougn) = mroxzvnuem rsqikyscsp (gaqkovwnzt )
-
09 Dec 2023
Phase 3
38
(Fedratimib)
tzqprzwues(xgkbjdvgdl) = hfkweihzdt mppqlywfnl (ianfzyrpxb, secicqmeal - zneupfkdrx)
-
09 Mar 2023
(Fedratinib)
hpleeftaiu(gbmyagbess) = tmsycctzbv bstdaocvxe (ztjbqnnsmc, ukpudpustl - cazoahfmas)
Phase 1/2
13
(ajdotcuspc) = qswdysoiuj yocbojpjqy (uwyliracwf )
Positive
15 Nov 2022
(ajdotcuspc) = rblqdixjph yocbojpjqy (uwyliracwf )
Phase 3
38
lzgdaazhty(aieemplygs) = vdtgvevaci ylhlsxdlyi (dmpcstgahe )
Positive
15 Nov 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free